Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]
We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]
Go to any support group meeting and you are almost sure to hear someone, usually a new member of the group, ask about what they might do to lower their risk of having their prostate cancer progress or even lower their risk of dying from the prostate cancer. Among the common answer to this question [...]
Approximately 2 years ago Malecare and the New York State Prostate Coalition began asking questions about where the State of New York was hiding approximately $3,000,000 in funding for prostate cancer research. Each year New York State residents are asked to check off a little box on their state tax return donating an additional dollar [...]
Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often [...]